lysosomal storage disorders

Josh Schafer Zevra CCO chief commercial officer

Pharma

Zevra pegs Miplyffa as 'cornerstone' of Niemann-Pick treatment

Zevra's commercial chief is confident that the company's new drug Miplyffa can become the “cornerstone” for treatment of Niemann-Pick disease type C.

Fraiser Kansteiner Oct 4, 2024 6:45am

stop light green

Zevra snags FDA approval for new lysosomal storage disorder med

Sep 20, 2024 1:54pm

BioMarin building

DOJ probing BioMartin testing programs for Vimizim, Naglazyme

Feb 28, 2024 7:48am